You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 31, 2012

Country Overview: Medical Devices in Thailand

Journal of Medical Device Regulation

Reproduced with the kind permission of Global Regulatory Press from the Journal of Medical Device Regulation, 2012, 9(3), 83-89 (www.globalregulatorypress.com).

Introduction

Now more than ever, the benefits and importance of healthcare have become more evident to Thai citizens. With the emergence of extensive research and development, rapidly advancing medical technology, and an overall improvement in awareness and education in the relevant field of law, the Thai population demands better standards of regulatory enforcement, an improvement in medical device provision and thus, in the long run, an overall increase in life expectancy.

Market research carried out in 2010 showed that the value of medical equipment imported into Thailand amounted to over THB 25 billion (around US$ 853 million) that year. The research also projected a likely average increase of 9% per year, or to THB 38 billion (around US$ 1.3 billion) in 2015.

Regulatory authority

In order to manufacture, import or sell a medical device in Thailand, it is crucial for medical device companies (manufacturers, importers and sellers) to understand fully the applicable local regulations. These are controlled by the Medical Device Control Division (MDCD) of the Thai Food and Drug Administration (TFDA).

Thai Food and Drug Administration, Ministry of Public Health
Medical Devices Control Division
Tiwanon Road, Nontaburi, Thailand
Tel: 66-2590-7244, 66-2590-7247, 66-2590-7249
Fax: 66-2591-8479, 66-2591-8480
E-mail: [email protected]

Legislative framework

The MDCD regulates and monitors the quality, standards, efficiency and safety of medical devices that are manufactured, imported and sold in Thailand, in accordance with the Medical Device Act of 2008 (B.E. 2551), related Ministerial Regulations, and Notices of the Ministry of Public Health. Important Ministerial Regulations are:

  • No. 1 B.E. 2533 (A.D. 1990), License for production – application requirements;
  • No. 2 B.E. 2533 (A.D. 1990), License for importation – application requirements;
  • No. 3 B.E. 2533 (A.D. 1990), License for distribution – application requirements;
  • No. 4 B.E. 2533 (A.D. 1990), Production, importation or distribution of notification medical devices;
  • B.E. 2552 (A.D. 2009), Fees for medical devices;
  • B.E. 2552 (A.D. 2009), Terms and conditions for registering a place of business for medical device production;
  • B.E. 2552 (A.D. 2009), Terms and conditions for registering a place of business for medical device importation.

Copies of the Medical Device Act of 2008 and all the Ministerial regulations may be accessed (in Thai) via the Government Gazette’s database (http://61.19.241.70/rkjnew/Front/ShowList.aspx?LawGroupID=53123&rkjTypeID=1).

Pre-approval of all medical devices is required before any commercial activity begins. It is also important to note that only locally established companies can import and register medical devices in Thailand.

Regulatory controls

Definition of a medical device

Contrary to popular belief, the definition of a medical device under Thai law is very similar to, and combines elements of, both the definitions used in the USA and the European Union (EU). The only difference is that the EU definition is narrower, as it is more detailed and excludes medical devices for animals, while the US definition does not include software. Section 4 of the Medical Device Act of 2008 defines medical devices as:

“(1) Instruments, apparatus, implements, machines, appliances, implants, in vitro reagents or calibrators, software, material or other similar or related articles, intended by the producer to be used alone, or in combination, for human beings or animals for one or more of the following specific purpose(s):

(a) Performing treatment in the medical profession, the nursing and midwifery profession, the dentistry profession, the medical technology profession, the physical therapy profession, and the veterinary profession, as prescribed by legislation related to performing other medical professions and public health as prescribed by the Minister;

(b) Diagnosing, preventing, monitoring, treating or alleviating disease in humans or animals;

(c) Diagnosing, monitoring, treating, alleviating or compensating for an injury to a human or an animal;

(d) Investigating, replacing, modifying or supporting the anatomy or the physiological process of the human body or in an animal;

(e) Supporting or sustaining the life of a human or animal;

(f) Controlling conception or helping with reproduction in a human or an animal;

(g) Helping, or helping to compensate for,a disability or infirmity in a human or an animal;

(h) Providing information for medical or diagnostic purposes, by means of an in vitro examination of specimens derived from the body of a human or an animal; and

(i) Destroying or disinfecting a medical device.

(2) Accessories or constituents in the instruments, appliances, machines, products, or articles under (1);

(3) Instruments, apparatus, machines, products or other articles prescribed by the Minister as a medical device.

Any of the outcomes as stipulated in the statement in (1), as they occur in a human body or animal, must not be derived from any pharmacology, immunology, or oxidation reaction aimed at creating energy as its main element.”

Classification

When introducing new products to the Thai market, many importers have important concerns about product classification. This is particularly because of the rapid pace of technological progress, which has advanced beyond the current TFDA regulations relating to medical devices. In addition, medical devices are complex and have many uses and benefits. Therefore, some medical devices, which are classified as such in other countries, may not necessarily be classified as medical devices in Thailand.

Although many countries rely on the US or EU classification systems, Thailand uses a different type of classification. Companies need to be aware that Thai classifications may be more or less stringent than their US/EU counterparts.

In Thailand, medical devices are classified into three classes based on the level of risk associated with the use of the device. This is a local Thai regulatory classification system, which appears to be applied in reverse order compared with the US/EU classification systems. The TFDA subjects Class III devices to the least stringent controls, and Class I devices to the most stringent controls.

Class I – Licensed Medical Devices

A Licensed Medical Device is the most strictly controlled class. Class I devices are usually those that support human life, are of substantial importance in preventing the impairment of human health, or prevent a potential or unreasonable risk of illness or injury. Examples of these devices include condoms, examination gloves, surgical gloves, contact lenses, and human immunodeficiency virus (HIV) test kits (for in vitro diagnostic use).

The Licensed Medical Device category requires the most information to be submitted for approval including, but not limited to, a Certificate of Analysis from the Department of Medical Sciences (DMSc), stability data, clinical study and/or evaluation data, a mandatory Thai label and leaflet, product formulae, and production processes. Such medical devices must meet the quality standards set out in the Notice of the Ministry of Public Health for each type of medical device.

Class II – Notification Medical Devices

A Notification Medical Device is subject to a less intensive review procedure than a Licensed Medical Device. As the name implies, the TFDA must be notified of Class II devices. Examples of Notification Medical Devices include HIV test kits (for investigational use and for research use), physical therapy products, alcohol detectors, implanted silicone breast prostheses, and equipment or instruments typically used for breast enhancement.

The information requirements for Notification Medical Devices are the same as those applicable for a Licensed Medical Device, except for some requirements such as the test results from the DMSc.

Class III – General Medical Devices

The requirements for General Medical Devices are the least stringent. Only the product description/information, product catalogue, and the Certificate of Free Sale need to be submitted to the TFDA for approval prior to marketing in Thailand. For some General Medical Devices, such as sterile products and laser equipment products, an ISO 13485 Certificate and technical data specifications are also necessary for approval.

Borderline products

Sometimes a healthcare product may overlap with, or be on the borderline between, the medical device, pharmaceutical and cosmetics legislation. If an applicant wishes to ensure that a product can be classified as a medical device under the Medical Device Act of 2008, the applicant may ask the TFDA to assess the product classification. The original documents from a manufacturer of the product which are required for the TFDA’s consideration are as follows:

  • details of the product (product name, the name and address of the manufacturer, product description, principle of operation/ mechanism, component material of the product, product specification, intended uses and indications, and instructions for use);
  • product catalogue;
  • product leaflet; and
  • supporting academic documents and/or government certificates from the manufacturing country showing the controlled status of the product (if needed).

The timeframe for the product classification process is officially 10 working days. However, for some difficult cases, the TFDA will need to forward the case to the Medical Device Committee for their consideration and determination. This additional review process may take more time.

Examples of differing classifications

Dermal fillers provide a good example of how the classification system in Thailand differs from other jurisdictions. Dermal fillers are considered to be Class IIb medical devices (generally regarded as medium risk) in the EU, and Class III (pre-market approval) in the USA. However, in Thailand, as of today, such products are still considered to be drugs. Thus, the process will be more stringent and, depending on the category, the requirements may be more burdensome, especially since companies would not necessarily be able to provide the quality, clinical and non-clinical parts required for new drugs, in accordance with the Association of Southeast Asian Nations (ASEAN) guidelines.

A similar problem exists for blood bag systems, which are currently classified as drugs in Thailand. The TFDA does not take into consideration the product (the bag) itself, but rather the component in the bag (blood) that is provided to the patient; it is this factor that determines the classification. However, the TFDA is in the process of adopting a new regulation that will classify blood bag systems as medical devices. This regulation is expected to be implemented in the near future.

Finally, products such as exercise machines used in hospitals may be classified as medical devices in Thailand, even though they are not classified as such in the USA/EU. This classification decision will depend on the intended use of the products as specified in the relevant product leaflets.

Advertising

It is mandatory to obtain an advertising license before undertaking any type of advertising or promotion for a medical device.

The concept of advertising has evolved over the past few decades. It no longer merely covers print materials such as publications, brochures, posters, or even television and radio advertisements. Today, online marketing of medical devices is also controlled in Thailand, especially via social networks or blogs.

Advertising must meet TFDA information requirements. For example, it must contain the name of the medical device, TFDA mandatory warnings, and the name of the importer and/or manufacturer. Information distributed on the Internet that is intended for customers or patients in Thailand must also meet these requirements.

The TFDA will review and consider the advertising application before issuing a license. According to Clause 7, Section 59 of the Medical Device Act of 2008, advertisements of medical devices must not:

  • show benefits, quality, volume, standard, components or the origin of the medical device, in a false or misleading manner;
  • show guarantee of benefits or endorsements by any person;
  • offer monetary compensation, or any other reward to patients, for the use of a medical device on a trial basis;
  • show benefits in respect of preventing, treating, mitigating or the healing of a disease or symptom, which the TFDA prohibits from being advertised; and
  • show any statements that may cause misunderstanding, in material part, in respect to the medical device.

Examples of words that cannot be used in medical device advertisements in Thailand are ‘excellent’, ‘special’, ‘the best’, ‘completely cured’, ‘holy’, ‘marvelous’, ‘safe’, ‘number one’, ‘no adverse effects’, ‘superior’, ‘most appropriate’, etc. These are some of the most well-known words that are prohibited. In order to determine whether particular words or phrases are acceptable, it is necessary to consider the use of the products themselves, and the construction of the messages.

When a license number has been obtained, it must be included in the advertisement. It is also important to note that an advertising license for a medical device is only valid for a period of three years from the date of issue.

Vigilance requirements

According to the Medical Device Act of 2008, Section 41(4), the registrant of the establishment, licensee, or notifier has to prepare a report on the abnormal performance or any adverse reactions of the medical device, and a report on its correction to the licensor, whether it happened in the country or abroad. However, it shall be made in accordance with the rules, procedures, and conditions prescribed by the Minister. Currently, there is no specific regulation under this Act. Therefore, the Ministerial Regulation No. 5 B.E. 2533 (A.D. 1990) on production, importation, and distribution report requirements should be followed.

The licensed and notified producer, importer, or distributor must submit an adverse event report in the event that the licensed and notified producer, importer, or distributor discovers an adverse event associated with the medical device. A report of the incident is required to be submitted to the Secretary General of the TFDA within 15 working days. In addition, if the adverse event is serious or causes death, it must be reported within 24 hours from the time the licensed and notified producer, importer, or distributor discovers such an adverse event.

Post-market surveillance

In order to ensure that companies comply with both the TFDA regulations and the advertisement requirements for medical devices, the TFDA conducts random post-marketing audits of companies.

Before product launch, the TFDA conducts a pre-marketing review, and it is highly protective of Thai consumers. As a developing country, Thai consumers rely heavily on the government to protect them. This is quite different from the practice in the USA, where product liability cases and class actions are often filed, which serves to deter companies from marketing harmful products. As part of its post-marketing reviews, the TFDA collaborates with other agencies, including the DMSc and provincial health offices, to monitor, inspect and follow up on pre-marketing controls.

According to the MDCD’s website, the main purposes for undertaking post-marketing audits are:

  • to protect the quality, safety and efficiency of medical devices for Thai people;
  • to monitor and follow up on trading, and indicate improper trends relating to medical devices;
  • to identify and punish whoever breaks the relevant medical device laws or regulations; and
  • to protect and persuade entrepreneurs to operate a legal business, and promote fair competition.

All registered medical device entrepreneurs also have mandatory duties to record and prepare a report for TFDA inspection relating to the quantities of medical devices manufactured, imported and sold in the Thai market, for a period of not less than five years from the manufacturing, importation or sales dates, and not less than one year from the expiry dates (if any). This requirement is set forth in the Notification of the Ministry of Public Health on the terms and conditions for the preparation of records, and for manufacturing, importing and selling reports, which has been effective since 7 February 2012.

All product registration holders also have to prepare and submit an annual report in respect of manufacturing, importing or selling medical devices, according to the TFDA’s report forms, as mentioned in the above Notification.

If a company does not comply with the TFDA requirements, the penalties are imprisonment not exceeding six months, or a fine not exceeding THB 50,000 (around US$1705), or both.

In practice, the TFDA has rarely issued public punishments for non-compliance in respect to advertising licenses. However, companies need to be aware that random audits still occur. If inspected, employees should report the inspection immediately to their supervisors, prior to agreeing to sign any report from the TFDA.

Clinical trial requirements

There are no specific regulations on clinical trials in Thailand. Thus, no clinical trial requirements are specifically tailored for medical devices. For clinical trials in general, the government relies on the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Good Clinical Practices Guidelines.

Labeling and language requirements

According to the Medical Device Act of 2008, section 44, the registrant of an establishment, licensee, or notifier who produces or imports medical devices shall provide a label and its accompanying document. This document should not include any false statement or overstate the truth.

However, the specific requirements for labels and/or accompanying documents (e.g., product leaflet) for each type of medical device are different. The requirements in regard to the label and/or leaflet for Licensed Medical Devices and Notified Medical Devices are mentioned in the Notification of Ministry of Public Health for each medical device.

Currently, there are no specific labeling requirements for General Medical Devices. However, the TFDA has announced a draft regulation on this matter.

Future changes

Thailand and the other nine ASEAN Member States are moving toward implementation of the ASEAN Economic Community (AEC) in 2015. The formation of a single market and a single production base in the region will permit companies within the AEC to move their capital freely, and will serve to break down effectively existing trade barriers that currently stunt intra-regional trade within the 10-member trading bloc.

The implementation of consistent standards within the ASEAN countries for each product, including related rules and regulations that conform to international standards, will in theory ensure the removal of trade barriers or obstacles. This process has already started for drugs and cosmetics.

With regard to the harmonization rules for medical devices, each ASEAN Member State has until 2014 to implement the new requirements established by the Medical Device Working Group, and to finalize the harmonization process for all medical devices. This includes formulating a common definition for medical devices (derived from the Global Harmonization Task Force definition), harmonizing the classification of products (five classes based on the assessed risk of the products), formulating a common list of international medical device standards in order to obtain similar quality assurance, and implementing a Common Submission Dossier Template (CSDT), among other requirements.

The TFDA has announced that is considering using the CSDT by 2012-2013, and preparations are underway for the implementation of the ASEAN Medical Device Directive within the next two years. Additionally, the TFDA is currently forcing local manufacturers to obtain Good Manufacturing Practice Certificates for their facilities, which are equivalent to international ISO 13485 certificates, for example.

RELATED INSIGHTS​ 

June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
December 15, 2023
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.